- Tempur Sealy International Inc (NYSE:TPX) reported fourth-quarter FY21 sales growth of 28.6% year-on-year, to $1.36 billion, missing the analyst consensus of $1.45 billion.
- Sales in North America rose 18.9% Y/Y, and the international segment sales gained 82.1%.
- The gross margin for the quarter contracted 140 basis points to 44.5%, and the gross profit rose 24.6% Y/Y to $604.5 million.
- The operating margin was 18.4%, and operating income for the quarter rose 29.8% to $250.8 million.
- The adjusted EBITDA jumped 24.2% Y/Y to $297.4 million.
- Adjusted EPS of $0.88 missed the analyst consensus of $0.95.
- The board of directors approved an 11% hike in quarterly cash dividend to $0.10 per share, payable on March 22, 2022, to shareholders of record on March 8, 2022.
- The company held $300.7 million in cash and equivalents as of December 31, 2021.
- Outlook: Tempur Sealy sees FY22 EPS of $3.65 – $3.85 versus the consensus of $3.76. The company’s current sales outlook is for year-over-year growth of 15% – 20%.
- Price Action: TPX shares are trading higher by 0.32% at $37.41 on the last check Tuesday.
NovoCure Q3 EPS $(0.13) Misses $(0.07) Estimate, Sales $133.60M Miss $141.76M Estimate
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.07) by 85.71 percent. This is a 244.44 percent decrease over earnings of $0.09 per share from the
